pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,106 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1173Endpoints890BioPharma Dive342BioSpace307Fierce Biotech290onclive165raps104globenewswire health73
therapy area
allOncology7582Rare Disease1868Cardiology1741Immunology1478Hematology1319Vaccines1197Pulmonology
  • NIH mulls grant cap to broaden funding across universities
    NIH officials are evaluating a proposal that would limit the number of research grants any single investigator can receive. The goal is to spread federal funding more evenly across institutions. R…
    STAT · 2mo agoRegulatoryPositive↗ source
  • HHS Secretary RFK Jr. says his calendar is public, but STAT finds no record after a year of requests
    Health secretary Robert F. Kennedy Jr. told reporters his calendar is publicly available as proof of his “radical transparency” pledge. STAT has filed Freedom of Information Act requests and email…
    STAT · 2mo agoRegulatoryNegative↗ source
← prev
page 90 of 125
next →
fda recalls69
fda medwatch60
fda press38
1171
Psychiatry & CNS866
Ophthalmology495
Pain480
Endocrinology & Metabolism473
Infectious Disease444
  • Open-access fees rise to $12,850 for NIH-funded study in Nature Medicine
    In 2025 a randomized clinical trial led by Elizabeth Selvin was published in Nature Medicine without any publication charge. The paper underwent peer review and editorial processing at no cost to t…
    STAT · 2mo agoNegative↗ source
  • Parabilis Medicines raises $670 million in record-setting biotech IPO on Nasdaq
    Parabilis Medicines, a Cambridge, Massachusetts drug developer, completed its initial public offering on Nasdaq, raising $670 million. The offering is described as the largest biotech IPO in indus…
    Endpoints · 3mo agoDealPositive↗ source
  • AstraZeneca advances obesity pill to Phase 3 after mid-stage trials show ~11% weight loss
    AstraZeneca announced that its experimental oral GLP-1 drug, elecoglipron, will enter an extensive Phase 3 development program following encouraging data from two mid-stage studies in obesity and d…
    BioPharma Dive · 3mo agoPositive readoutPositive↗ source
  • Parabilis raises $670M in record-setting Nasdaq debut to fund cancer drug development
    Parabilis completed a $670 million initial public offering on the Nasdaq, establishing the largest biotech debut in the exchange’s history. The offering drew strong investor demand even as attenti…
    Endpoints · 3mo agoDealPositive↗ source
  • Parabilis raises record $670 million in biotech IPO, the largest for a venture-backed company
    Parabilis Medicines, a biotech focused on "undruggable" targets, completed an initial public offering that raised $670 million, the biggest amount ever for a venture-backed biotech. The company so…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Sanofi halts Phase 3 trial of riliprubart in CIDP after interim analysis shows unlikely efficacy
    Sanofi announced Wednesday that it is stopping the Phase 3 MOBILIZE study of its experimental anti‑inflammatory drug riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (…
    BioPharma Dive · 3mo agoNegative readoutNegative↗ source
  • US judge upholds law to curb hospital drug prices as shortage trends show mixed signals
    A federal judge in Washington rejected a pharmaceutical industry challenge to a state law aimed at lowering hospital drug prices, leaving the pricing reforms in place. Data from a recent analysis…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Europe’s drug pricing split: UK leans pro‑industry while Germany eyes cuts and higher fees
    European nations are feeling mounting pressure to rein in drug prices, a trend that is reshaping the market for both manufacturers and patients across the continent. In the United Kingdom, lobbyin…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Beren Therapeutics secures $300 million to fund rare disease drug launch ahead of FDA review
    Beren Therapeutics announced it has raised $300 million in new financing to support the development and launch of its rare disease therapy. The funding arrives as the company prepares for an FDA d…
    Endpoints · 3mo agoDealPositive↗ source
  • Ethyreal Bio raises $101M to develop antibody targeting Graves disease and thyroid eye disease
    Ethyreal Bio, a Cambridge-based biotech that has just emerged from stealth mode, announced it has closed a $101 million financing round to advance its lead candidate. The company’s candidate, a mo…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Novartis inks second molecular glue partnership with Orionis, $40M upfront
    Novartis has entered a second agreement with Orionis Biosciences focused on molecular glue technology. The deal includes an upfront payment of $40 million. The agreement also provides for mileston…
    Endpoints · 3mo agoDealPositive↗ source
  • SonoThera secures $125 million to advance ultrasound-based gene therapy for Duchenne and polycystic kidney disease
    SonoThera announced it has raised $125 million in financing to move its ultrasound-based non-viral gene therapy platform toward clinical testing. The funding will support the company’s two lead pr…
    Endpoints · 3mo agoDealPositive↗ source
  • Sanofi halts rare disease trial as Parabilis launches record biotech IPO amid European pricing debate
    Sanofi announced it is stopping a Phase 3 trial of its experimental drug riliprubart in a rare autoimmune disease after an interim analysis showed the treatment did not work. The pause adds to rec…
    STAT · 3mo agoNeutral↗ source
  • Shattuck Labs raises $75M in public offering, selling 10.5M shares at $4 each
    Shattuck Labs announced a $75 million public offering to raise capital. The company is selling more than 10.5 million shares at $4 per share and is also issuing pre‑funded warrants to selected inv…
    Endpoints · 3mo agoDealNeutral↗ source
  • Biotech executives pocket nearly $1 billion in M&A golden parachutes, 12 receive $35M+ payouts
    An Endpoints News analysis identified a group of twelve biotech leaders who collectively earned close to $1 billion in exit compensation after selling their companies. Each of these executives sec…
    Endpoints · 3mo agoNegative↗ source
  • Ethyreal Bio secures $101M to develop treatments for Graves' disease and thyroid eye disease
    Ethyreal Bio, a newly unveiled biotech, announced it has raised $101 million in financing. The round was led by venture firms Atlas Venture and Medicxi. The capital will be used to advance therape…
    Endpoints · 3mo agoDealPositive↗ source
  • Sanofi halts Phase 3 trial of riliprubart in rare neurological disorder
    Sanofi announced it is ending the Phase 3 study of its antibody drug riliprubart aimed at treating a rare neurological disease. The decision follows a recommendation from an independent data monit…
    Endpoints · 3mo agoNegative readoutNegative↗ source
  • Republican pushback on methadone and buprenorphine raises concerns among addiction experts
    Recent guidance from the Trump administration has revived a debate over the use of methadone and buprenorphine for opioid addiction treatment, prompting renewed scrutiny of federal policy. Addicti…
    STAT · 3mo agoRegulatoryNegative↗ source
  • DOJ announces second settlement on youth gender-affirming care amid broader health news
    The Department of Justice disclosed that it has reached a second settlement with parties involved in providing gender-affirming care to minors. The agreement, announced in a recent newsletter, buil…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • ADA CEO apologizes for expelling five members over protest literature, vows review and trust rebuilding
    Five members of the American Diabetes Association were removed from its annual scientific sessions in New Orleans after distributing editorial material that criticized federal research funding cuts…
    STAT · 2mo agoNegative↗ source
  • ACOG issues new pregnancy vaccine schedule that diverges from CDC guidance
    The American College of Obstetricians and Gynecologists (ACOG) released a new vaccine schedule for pregnant individuals that differs from the current CDC guidance. ACOG recommends four vaccines be…
    STAT · 3mo agoNeutral↗ source
  • Nevada Supreme Court blocks enforcement of teen abortion notification law, expanding access
    The Nevada Supreme Court issued a unanimous order on May 28 that temporarily halts the enforcement of the state’s 1985 parental notification requirement for abortions. The preliminary injunction al…
    STAT · 3mo agoRegulatoryPositive↗ source
  • AI sepsis tools face timing challenges, says STAT AI Prognosis newsletter
    The latest STAT AI Prognosis newsletter notes that current sepsis detection algorithms sometimes require data from future time points, which is unrealistic. The piece highlights how such quirks in…
    STAT · 3mo agoNeutral↗ source